Drugs / CD4CAR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06197672 | Mar 2024 → Dec 2027 expected | acute myeloid leukemia | Huda Salman | Recruiting | No outcome recorded |
| Phase 1 | NCT06071624 | Feb 2024 → Dec 2028 expected | chronic myelomonocytic leukemia | Huda Salman | Recruiting | No outcome recorded |
| Phase 1 | NCT03829540 | Jul 2020 → Dec 2027 expected | T-cell leukemia, T-cell non-Hodgkin lymphoma | Huda Salman | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD4CAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03829540 ↗ |
| Modality | Cell therapy | “autologous CD4CAR T-cells” NCT03829540 ↗ |
| Route | Intravenous | “The route of administration is by IV infusion” NCT03829540 ↗ |
| Target | CD4 | “CAR targeting CD4” NCT03829540 ↗ |